Objective: Long non-coding RNAs (lncRNAs) exert a critical function in mediating neuropathic pain (NP). MEG3, a novel lncRNA, contributes to astrocyte activation and inflammation. However, its role in NP remains unclear. Methods: The chronic constriction injury (CCI) method was employed to construct an NP rat model. Astrocyte activation was induced by lipopolysaccharide (LPS). The profiles of MEG3, microRNA (miR)-130a-5p, CXC motif chemokine receptor 12 (CXCL12)/CXC motif chemokine receptor 4 (CXCR4), and the Rac1/NF-κB pathway in CCI rats’ spinal cord tissues and astrocytes were monitored by reverse transcription-quantitative PCR (RT-qPCR) and western blot (WB). Pain scores of CCI rats were assessed. Enzyme-linked immunosorbent assay (ELISA) was adopted to monitor neuroinflammation alteration. The glial fibrillary acidic protein (GFAP)-labeled astrocytes were tested by immunohistochemistry (IHC). Bioinformatics, dual-luciferase reporter assay and RNA immunoprecipitation (RIP) were utilized to verify the molecular mechanism between MEG3 and miR-130a-3p. Results: MEG3, CXCL12 and CXCR4 were overexpressed and miR-130a-5p was knocked down in CCI rats and LPS-induced astrocytes. Up-regulating MEG3 aggravated NP, enhanced inflammatory cytokines interleukin-1β (IL-1β), tumor necrosis factor (TNF)-α, and interleukin-6 (IL-6) expression and release in CCI rats and LPS-induced astrocytes. Up-regulating miR-130-5p repressed LPS-induced inflammation in astrocytes. AS verified by the dual-luciferase reporter assay and RIP assay, MEG3 sponged miR-130a-5p as a competitive endogenous RNA (ceRNA). What’s more, miR-130a-5p up-regulation weakened the MEG3-induced proinflammatory effects on LPS-induced astrocytes. Conclusions: MEG3 aggravates NP and astrocyte activation via the miR-130a-5p/CXCL12/CXCR4 axis, which is a potential therapeutic target for NP.

The objective of the present study was to investigate the effect of highly selective peripheral nerve radiofrequency (RF) ablation for the pain caused by severe knee osteoarthritis (OA). A total of 96 patients with knee OA were randomly divided into two groups. The 49 patients in group A were treated with highly selective peripheral nerve RF ablation group and the 47 patients in group B were treated with sodium hyaluronate injection. Visual analogue scale (VAS), Lysholm knee score (LKS), and pain relief before treatment and at 3 days and 3, 6, 9, and 12 months after treatment were compared. At each time point after treatment in group A, both VAS and LKS scores were significantly different compared with before treatment (P<0.05). At 3 days, and at 3 and 6 months after treatment in group B, VAS scores were significantly different from before treatment (P<0.05) and at 9 and 12 months after treatment, the scores were not significantly different from those before treatment. In addition, LKS scores were only significantly different at 3 months after treatment compared with before treatment (P<0.05) and not significantly different after that time point. Furthermore, compared with group B, the rates of effective pain relief in group A were significantly higher at each time point after treatment (P<0.05). Compared with sodium hyaluronate injection, highly selective peripheral nerve RF ablation of the knee was more effective, easy to operate and had no significant adverse effects for the treatment of knee OA.